Radiotherapy is an essential and effective treatment modality for cancer. Excessive levels of reactive oxygen species (ROS) induced by ionizing radiation disrupt the redox homeostasis and lead to oxidative stress that may result in cell death. However, the tumor cell microenvironment is dynamic and responds to radiotherapy by activating numerous cellular signaling pathways. By scavenging excess ROS, the activity levels of the endogenous antioxidant enzymes result in radioresistance and worsen the clinical outcomes. To assess the full potential of radiotherapy, it is essential to explore the underlying mechanisms of oxidative stress in radiotherapy for potential target identification. The present review article summarized recent data demonstrating nuclear factor-erythroid factor 2-related factor 2 (Nrf2) as a powerful transcription factor and one of the major cellular defense mechanisms that protect against oxidative stress in response to radiotherapy; the glutathione (GSH) and thioredoxin (Trx) systems complement each other and are effective antioxidant mechanisms associated with the protection of cancer cells from radiation damage. In addition, it is suggested that dual targeting to inhibit GSH and Trx enzymes may be a potential strategy for the development of radiosensitive and radioprotective drugs.
oxidative stressradiotherapyradiosensitivityglutathione metabolismthioredoxinNational Natural Science Foundation of China81773363818725588197296981673092The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 81773363, 81872558, 81972969 and 81673092).1. Introduction
Oxidative stress generally originates from toxic by-products resulting from the imbalance between radicals and antioxidants, which primarily arises from the accumulation of reactive oxygen species (ROS) (1,2). The redox balance is maintained by complex cellular biochemical and genetic mechanisms. Redox imbalance may have profound effects on physiological and pathophysiological mechanisms (3,4). ROS disrupt cellular processes by non-specific modifications on critical amino acid residues in proteins (resulting in protein oxidation), fatty acids in lipids (to cause lipid peroxidation) and nucleic acids (inducing DNA damage and strand breaks) (5-8). ROS mainly includes the superoxide anion (O2−), hydrogen peroxide (H2O2), hydroxyl radical (·OH) and singlet oxygen (1O2) (9). Among these, ·OH is the most reactive ROS and is able to react with almost any tissue directly, thereby causing more effective cellular damage than any other ROS (10). Under pathological conditions, tumor cells produce elevated levels of ROS compared with those of normal cells (11-13). Tumor cells always adjust their metabolism to increase intracellular ROS levels and maintain their survival and proliferation during tumorigenesis (14,15). However, ROS have a dual role in cancer development. ROS may lead to epigenetic alterations that promote the acceleration of tumor progression. By contrast, higher levels of ROS promote genome instability, inducing activation of cancer cell death or inhibiting resistance to anticancer treatment (16-19).
Theoretically, radiotherapy is able to more precisely target the tumor. The relative toxicity caused by radiation to the surrounding normal tissues is limited (20). However, several antioxidant transcription factors may be activated in response to radiotherapy, resulting in the inhibition of ROS-dependent damaging effects induced by radiation and in the reduced effectiveness of the treatment (21). In addition, the source of ROS is considered to be a double-edged sword, which has a key initiator role in ionizing radiation (IR)-associated normal tissue injury (22). The radioresistance and tumor recurrence following radiotherapy are significant problems to overcome, which may contribute to treatment failure and tumor relapse. Specific modifications in the production of ROS and the concentrations of antioxidants have pivotal roles in cancer radiotherapy (12,23,24). Current research demonstrates that targeting oxidative stress may benefit patients with radiation resistance during radiotherapy (25). Therefore, the identification of the mechanisms of oxidative stress has been the focus of various studies. In the present review article, the mechanisms underlying the regulation of oxidative stress induced by radiotherapy were summarized and the benefits of using radio-protectors or radio-sensitizers were discussed.
2. Molecular mechanisms and pathways of oxidative stress
The current literature was reviewed and oxidative stress-related genes were extracted from pertinent papers (Table SI). Finally, 198 gene symbols were confirmed with the HUGO Gene Nomenclature Committee Multi-symbol checker tool (https://www.genenames.org/tools/multi-symbol-checker). Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis by R software was used to identify the signaling pathways that were mainly enriched by oxidative stress-related genes. Fig. 1 indicates the significant pathways identified (rich factor >0.1), which were sub-grouped by the KEGG main class. The top significant pathways with roles in cellular processes were as follows: Ferroptosis, apoptosis, p53 signaling pathway, mitophagy, cellular senescence pathway and autophagy. In addition, the forkhead box protein O (FoxO), Erb-b receptor tyrosine kinase (ErbB), vascular endothelial growth factor receptor (VEGF), hypoxia inducible factor-1 (HIF-1), TNF, mTOR, NF-κB, MAPK, 5′AMP-activated protein kinase, Janus kinase/signal transducer and activator of transcription, Ras and PI3K/AKT signaling pathways were the most represented pathways according to environmental information processing. Glutathione (GSH) metabolism was dominant in the metabolism category.
As protectors of cancer cells from the effects of ROS, the superoxide dismutase (SOD), GSH reductase (GPX), thioredoxin (Trx) reductase (TrxR) and catalase (CAT) antioxidant enzymes were investigated, which have a major role in ROS scavenging (26-28). Fig. 2 indicates the response of the antioxidant system to radiotherapy. SODs may function in different cellular compartments to rapidly catalyze O2− into H2O2 and O2. The other antioxidant enzymes, including CAT, GPX and TrxR, convert H2O2 into water (29). In mammalian cells, the following three types of SOD exist: A copper and zinc SOD termed CuZn-SOD or SOD1, which is mainly found in the cytosol, a manganese SOD, termed Mn-SOD or SOD2, which is found in the mitochondrial matrix, and an extracellular SOD termed EC-SOD or SOD3 (30). CAT is located primarily in the peroxisomes and is a widespread and highly efficient antioxidant enzyme present in almost all living organisms, which uses either iron or manganese as a cofactor (31). The GSH system, which is composed of glutathione reductase (GR), GSH and NADPH, is the most abundant cellular thiol antioxidant system and is regulated by its biosynthesis, redox state and cellular export (32). Its redox cycle is regulated by GPX and GR (33). At least eight isoforms of GPX enzymes (GPX1-GPX8) have been found in mammals, of which GPX4 is the only one that is able to reduce phospholipid hydroperoxides (34,35). The solute carrier family 7 member 11 (SLC7A11) has a pivotal role in intracellular cysteine balance and GSH biosynthesis (36). Similar to the GSH system, Trx is another powerful cellular disulfide reductase involved in the control of cellular redox homeostasis, which comprises TrxR, Trx and NADPH (37). The mammalian Trx consists of the following three isoforms: Trx1 in the cytosol, Trx2 in the mitochondria and a testis-specific Trx. The following three types of TrxRs have been characterized: Cytosolic TrxR1, mitochondrial TrxR2 and testis-specific TrxR3 (38). Trx donates electrons to peroxyredoxin (Prx) to remove H2O2. Typically, the Trx and GSH systems are functioning in parallel, and several types of reciprocal crosstalk have been identified between these two systems, indicating that the components of one system may be a backup to those of the other (38).
3. Functional characterization of oxidative stress in radiotherapy
Radiotherapy has been recognized as one of the mainstay regimens for various types of cancer treatment (39,40). The changes in the biological effectiveness of the targeted tissues caused by IR are related to the energy deposits observed in the encountered molecules of specific cell signaling pathways (41,42). Oxidative stress has a powerful function in cancer progression and in the response to radiotherapy. IR-induced cell damage may originate from direct or indirect actions. Direct damage to the cell mainly relies on the radiation that affects the DNA molecules and results in the formation of either single- or double-strand breaks (43). By contrast, water radiolysis rapidly produces ROS; the elevated intracellular levels of ROS cause oxidative stress, which results in indirect damage. Approximately 80% of the cellular content is composed of water, which has a leading role in IR-induced biological effects (42,44).
The radiolysis of water leads to the formation of free radicals, such as hydrated electrons (e−aq), ·OH, and H·, and certain molecular products (H2, H2 O2) (45,46). E−aq are able to indirectly form O−2 with molecular oxygen (47). In addition, H2O2 and O2− may be transformed into the highly reactive ·OH via the Fenton or the Haber-Weiss reactions in the presence of transition redox metals, such as iron or copper (48). IR generates ROS that readily interact with cellular membrane lipids, proteins and nucleic acids, resulting in the alteration of membrane permeability, proteolytic degradation, DNA damage and genomic instability. This eventually induces radiation damage and tumor cell death (49). Consequently, radiotherapy may efficiently induce massive cell death by increasing intracellular ROS levels. Furthermore, the radiation damage also affects adjacent normal cells via the bystander effect (50-52). Radiotherapy used in cancer treatment may cause problems in the heart, as well as in the hematopoietic, intestinal and nervous systems (53,54).
4. Activation of oxidative stress pathways by radiotherapy
The results of the KEGG pathway analysis revealed that the dominant pathways that regulate oxidative stress were the ferroptotic (Fig. S1), apoptotic (Fig. S2), FoxO (Fig. S3) and ErbB (Fig. S4) signaling pathways. All of these pathways may be activated by radiotherapy (55-58). To respond to IR-induced oxidative stress and the change in redox environmental conditions, multiple signal transduction pathways crosstalk with each other (Fig. 3). Depending on the IR dose, the dose rate, the quality and the time period of treatment, these mechanisms may affect the antioxidant or pro-oxidant effects in a different manner. To clarify the crosstalk between oxidative stress and the intracellular IR response, the corresponding molecular mechanisms were investigated. These molecular events were involved in the relationship between the major pathways linked to oxidative stress and the response of the antioxidant defense pathways to radiotherapy.
Ferroptotic pathway
Ferroptosis is a recently described form of regulated cell death, which differs from apoptosis and necrosis and is characterized by the accumulation of iron-dependent lipid peroxidation (59,60). The critical role of ferroptosis in radiotherapy has been established in recent studies (55). The cell membrane is the major target of IR-induced ROS, since membrane lipids are easily peroxidized, resulting in structural and functional damage (61). Glutathione metabolism is one of the main mechanisms governing ferroptosis. GPX4 and SLC7A11 are key regulators of glutathione metabolism, which have a crucial role in limiting lipid peroxidation (62).
Radiotherapy results in downregulation of SLC7A11 expression and induces lipid oxidative damage to promote tumor-associated ferroptosis (63). IR may also cause significant downregulation in the expression levels of GPX4 (64). However, in certain cases, IR may induce SLC7A11 or GPX4 expression as an adaptive response to protect cells from ferroptosis (65). In addition, p53 and nuclear factor-erythroid factor 2-related factor 2 (Nrf2) may be rapidly activated by IR, which has an important role in the regulation of ferroptosis. p53 is able to inhibit the cellular uptake of cystine by transcriptionally restricting SLC7A11 expression to reduce antioxidant capacity, resulting in ferroptosis (66,67). The transcription factor Nrf2 is considered to have a central role in the upregulation of the expression levels of specific anti-ferroptotic defense biomarkers. Nrf2 promotes cell survival in irradiated cells via activation of specific downstream regulator target genes, including SLC7A11. These genes aim to prevent oxidative damage (68-71). In addition, the Trx system may also protect cells from lipid peroxidation (72). Nrf2 is able to bind to the TrxR1 and Trx1 promoter antioxidant responsive element (ARE) and improve its activity (73). In addition, it has been indicated that Nrf2 is able to bind to the ARE sequence of various other antioxidant proteins, namely GPX2, Prx1, Prx6 and glutamate-cysteine ligase catalytic subunit (74-77).
Apoptotic pathway
Apoptosis is a form of regulated cell death. Oxidative stress is considered to be a strong inducer of apoptosis (78). Apoptosis is triggered by the following two major signaling pathways: The extrinsic and the intrinsic pathway. These pathways are independent but interact with each other (79). It is suggested that both the intrinsic pathway (activated by mitochondrial outer membrane permeabilization) and the extrinsic pathway (initiated by plasma membrane receptors) may be activated following IR treatment (80).
However, studies have demonstrated that radiotherapy primarily acts through the intrinsic pathway (80-82). The signatures of several intrinsic pathway proteins are associated with radiosensitivity, such as p53, Bcl-2 and Bax (83,84). In response to IR-induced oxidative stress, p53 has an essential role in the regulation of the redox state (85,86). The activation of p53 is largely dependent on the ATM kinase that phosphorylates p53 shortly after IR (87). A previous research study suggested that p53 regulated radiotherapy efficacy by targeting Bcl-2 proteins to release Bax, which in turn promoted apoptosis or inactivated invasiveness (88). In addition, p53 was also able to activate the expression levels of SOD2 and GPX1 by binding to their promoters, which stimulates an antioxidant response (89). It is known that TNFα is a potent pro-apoptotic molecule, which promotes the expression of several inflammatory factors. However, TNFα also has a role in cell survival mechanisms (90-92). TNFα is able to increase the transcription of GPX4 (93). Activation of the transcription factor NF-κB has a central role in regulating apoptosis (94). In addition to its apoptotic activity, NF-κB induces the expression of specific genes, which may attenuate ROS production and promote survival (95). For instance, the NF-κB pathway may lead to SOD2 gene activation (96,97). Experimental evidence also suggests that GPX4 is transcriptionally regulated by NF-κB (93).
FoxO signaling pathway
The FoxO family includes several pivotal transcription factors activated in response to oxidative stress, such as FoxO1, FoxO3a, FoxO4 and FoxO6. The majority of previously published studies have focused on the first three members (98,99). The interaction of FoxO and p53 proteins may coordinate tumor suppression via the regulation of various common target genes, such as p21, growth arrest and DNA damage, protein phosphatase 1D and sestrin 1 (57). A previous study revealed that JNK is able to phosphorylate FoxO1, FoxO3a, and FoxO4 to facilitate nuclear entry of FoxO, leading to the upregulation of the expression levels of antioxidant genes (98).
FoxO3a is a crucial effector of IR-induced apoptosis in response to genotoxic stress (100). FOXO3a promotes the cell survival pathway by directly binding to the SOD2 promoter, causing increased expression of SOD2. The activation of the latter protects the cells from oxidative stress-mediated injury (101). By contrast, FoxO3a may effectively increase cellular antioxidant capacity by enhancing the levels of CAT and Prx3 to protect against oxidative stress (102,103). However, the regulation of oxidative stress by FoxO3a is complex. A previous study indicated that depletion of FoxO3a expression profoundly reduced kelch-like ECH associated protein 1 protein levels, thereby activating Nrf2 signaling (104). It was also indicated that FoxO4 was able to bind to the SOD2 promoter to upregulate SOD2 expression (105). FoxO1 was able to promote activating transcription factor 4 expression, which acts as an important transcription factor for SLC7A11, leading to GSH synthesis (106,107).
ErbB signaling pathway
The ErbB family of proteins is also termed the epithelial growth factor receptor (EGFR) family and consists of the four following members: EGFR (ErbB1 or Her1), ErbB2 or Her2, ErbB3 or Her3, and ErbB4 or Her4 (108). In response to IR, the ErbB receptor tyrosine kinase family is rapidly activated, leading to subsequent activation of multiple downstream pathways (58,109). The activated downstream pathways mainly include PI3K/AKT, MAPK/ERK1/2, Ras and the mTOR signaling pathways, leading to alteration in cell proliferation, apoptosis, autophagy, migration and invasion (110-112). The EGFR transactivation caused by ROS results in the protection of the cells against oxidative stress with extensive crosstalk occurring among these pathways (113).
ErbB receptors, notably EGFR and ErbB2, are closely associated with the induction of oxidative stress (114). EGFR may stimulate HIF signaling activity to improve cellular survival (115). A previous research study has identified a functional transcription start site for GPX3, which is used for binding with HIF-1 (116). Several mechanisms have also been reported to explain the increase in Nrf2 transcription by the PI3K/AKT and Kras signaling pathways (117). The study also indicated that ErbB2 activated Nrf2 transcriptional activity through direct protein-protein interactions, which caused the induction of the expression of antioxidant and detoxification proteins (118). Moreover, Sakurai et al also reported that overexpression of Nrf2 augmented the TrxR1 promoter activity (119). In addition, it has been demonstrated that the restriction of ErbB2 receptor contributes to cell death through the production of ROS (120).
It is important to note that IR-induced ROS leads to cellular oxidizing stress that has an important role in radiotherapy. Several proteins are related to the regulation of the antioxidant systems. These proteins control the expression of various antioxidant genes and may defend against the induction of oxidative stress by IR (Table I). Consequently, the effects of various types of anticancer treatment may be diminished.
5. Oxidative stress acts as a mediator of radiosensitivity
IR-induced oxidative stress is not only involved in cancer cell death but also in the activation of the damage-repair and survival signaling to relieve the induction of oxidative damage. These activations are responsible for radioresistance in cancer (85). The inhibition of oxidative stress appears to be the main mechanism, established by the intracellular antioxidant system, responsible for tumor radioresistance (121). As presented in Table II, increasing evidence has demonstrated that antioxidant system inhibitors promote radiation sensitization.
Previous studies have suggested that Nrf2 is a key transcription factor that regulates the expression of various antioxidant proteins (122,123). Nrf2 inhibitors may be an effective approach against radioresistance. ML385 is a specific Nrf2 inhibitor that binds this transcription factor and blocks the downstream target gene expression, leading to the sensitization of breast cancer stem cells to IR (124). Brusatol selectively reduces the protein levels of Nrf2 by enhancing ubiquitination and degradation of Nrf2 and enhances the radiosensitivity of tumors (125). In addition, IM3829 markedly enhances the radiosensitivity of human lung cancer cells by inhibiting the mRNA and protein expression levels of Nrf2 (126). Halofuginone, a less-toxic febrifugine derivative, is considered to be particularly promising for cancer treatment. This compound rapidly suppresses the accumulation of the Nrf2 protein in therapy-resistant cancer cells (127). Although FoxO3a may be activated by IR, leading to an increase in the expression levels of antioxidant markers, FoxO3a-induced apoptosis has received increasing attention in response to radiation. Butyrate (128) and resveratrol (129) have demonstrated the potential to overcome the radioresistance effect by enhancing the activation of FoxO3a transcription. During radioresistance, ferroptosis inducers also have a key role. A previous study revealed that sulfasalazine (inhibitor of SLC7A11) and RSL3 (inhibitor of GPX4) exert significant radiosensitizing effects in vitro (65). TrxR inhibitors enhance radiosensitivity by triggering excessive oxidative stress. Specific examples of these compounds include auranofin (72,130), platinum complexes (20) and selenadiazole (131,132). Since Trx and GSH perform crosstalk with each other, their dual inhibition has synergetic antitumor effects in cancer therapy by inducing ROS production (133). EGFR or ErbB2 inhibitors (e.g. lapatinib) led to increased radiosensitivity in wild-type K-ras pancreatic cancer (134). The EGFR inhibitor icotinib has been indicated to increase radiosensitivity by enhancing apoptosis and downregulating the MAPK-AKT and ERK signaling pathways (135). In addition, combination treatment with radiotherapy and an MDM2-p53 inhibitor (APG-115) made tumors overcome radioresistance and enhance the antitumor effects (136).
6. Antioxidants act as radioprotective agents
Typically, IR causes the accumulation of endogenous ROS in irradiated cells, as a consequence of the activation of intracellular signaling pathways (137-139). These effects result in an ongoing inflammatory cascade, which may contribute to continuous damage that surpasses the initial insult and responses noted in non-irradiated cells, which are neighboring to irradiated cells (IR-induced bystander effects) (140). The side effects of IR mostly result from the increased oxidative stress and inflammation generated during radiotherapy (141). Therefore, it is of particular importance that the induction of tumor cell death during radiotherapy occurs without producing extensive damage to surrounding healthy tissues (142).
To reduce these adverse effects, radioprotectors are employed to protect against IR damage to healthy tissues. These compounds act by different mechanisms, which are mainly associated with the modulation of the antioxidant defense (49). p53 inhibition may reduce damage to normal tissues and this strategy has been experimentally tested in mice by using a small-molecule inhibitor of p53 (pifithrin-α) (143). Isofraxidin may have a radioprotective effect in human leukemia cells through decreasing ROS levels in a p53-independent manner (144). Resveratrol has been indicated to attenuate IR enteritis by inhibiting oxidative stress and apoptosis through the activation of the Sirtuin 1/FoxO3a and PI3K/AKT signaling pathways (145). In addition, the endogenous compounds melatonin and vitamin D are considered to be potent radioprotectors for the protection against oxidative damage caused by IR (146). Melatonin has been reported to possess significant potency in inhibiting the induction of oxidative stress via regulation of the expression levels of certain antioxidant genes (including Nrf2) and the activities of ROS/nitric oxide-producing enzymes (147). In addition, this hormone may directly scavenge free radicals to alleviate oxidative injury induced by IR in different cells or organs (147). In previous studies, plant and plant-derived products, such as herbal medicine, have been extensively examined for their effectiveness and compatibility in conferring radioprotection (49). Mn porphyrins are powerful SOD mimics, which have been indicated to possess radioprotective effects in different cells, animal models and tissues, including the lung, the prostate and the brain (148,149). The lead Mn porphyrins, such as MnTE-2-PyP5+ (BMX-010, AEOL10113), MnTnBuOE-2-PyP5+ (BMX-001) and MnTnHex-2-PyP5+ have entered clinical trials for the assessment of their efficacy in the radioprotection of normal tissues during cancer radiotherapy (149).
7. Conclusions
Accumulating evidence suggests that a rational combination of antioxidants or oxidants with IR is an attractive approach to improve the tumor treatment response. In the present review article, the molecular pathways and potential candidate targets that control the induction of oxidative stress in radiosensitivity and radioprotection were discussed. Nrf2 was identified as a key transcriptional target involved in the resistance of cancer cells to radiotherapy. In addition, Trx and GSH complement each other. They are parts of powerful antioxidant mechanisms connected with the protection of cancer cells from radiation resistance. However, due to the limitations of the present study, further experiments should be performed to completely uncover the roles of these antioxidant enzyme systems in radiotherapy. A deeper understanding of the mechanisms underlying oxidative stress in cancer radiotherapy may reveal novel therapeutic opportunities.
Supplementary DataAvailability of data and materials
All data generated or analysed during this study are included in this published article.
Authors' contributions
RL and YB contributed to the preparation, bioinformatics analyses and drafting of the manuscript. RL, YB, LL and LCL performed the relevant literature search, assisted in obtaining data and revised the manuscript. XDL and SMM supervised the preparation of the manuscript and critically reviewed the manuscript. All authors have read and approved the final version of the manuscript. Data authentication is not applicable.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Acknowledgments
Parts of the figures were adapted using Servier Medical Art (https://smart.servier.com/), licensed under Creative Commons Attribution 3.0 Unported (CC BY 3.0).
ReferencesZhangZRongLLiYPFlaviviridae viruses and oxidative stress: Implications for viral pathogenesisOxid Med Cell Longev2019140958220196720866PizzinoGIrreraNCucinottaMPallioGManninoFArcoraciVSquadritoFAltavillaDBittoAOxidative stress: Harms and benefits for human healthOxid Med Cell Longev20178416763201710.1155/2017/8416763288195465551541HayesJDDinkova-KostovaATTewKDOxidative stress in cancerCancer Cell38167197202010.1016/j.ccell.2020.06.001326498857439808BeyfussKHoodDAA systematic review of p53 regulation of oxidative stress in skeletal muscleRedox Rep23100117201810.1080/13510002.2017.1416773292981316748683PisoschiAMPopAIordacheFStancaLPredoiGSerbanAIOxidative stress mitigation by antioxidants-An overview on their chemistry and influences on health statusEur J Med Chem209112891202110.1016/j.ejmech.2020.112891ZuoLWijegunawardanaDRedox role of ROS and inflammation in pulmonary diseasesAdv Exp Med Biol1304187204202110.1007/978-3-030-68748-9_1134019270CzarnockaWKarpińskiSFriend or foe? Reactive oxygen species production, scavenging and signaling in plant response to environmental stressesFree Radic Biol Med122420201810.1016/j.freeradbiomed.2018.01.01129331649Samavarchi TehraniSMahmoodzadeh HosseiniHYousefiTAbolghasemiMQujeqDManiatiMAmaniJThe crosstalk between trace elements with DNA damage response, repair, and oxidative stress in cancerJ Cell BiochemOct302018Epub ahead of print30378148PingZPengYLangHXinyongCZhiyiZXiaochengWHongZLiangSOxidative stress in radiation-induced cardiotoxicityOxid Med Cell Longev20203579143202010.1155/2020/3579143321901717071808WangXQWangWPengMZhangXZFree radicals for cancer theranosticsBiomaterials266120474202110.1016/j.biomaterials.2020.120474ZhangJDuanDSongZLLiuTHouYFangJSmall molecules regulating reactive oxygen species homeostasis for cancer therapyMed Res Rev41342394202110.1002/med.21734MoloneyJNCotterTGROS signalling in the biology of cancerSemin Cell Dev Biol805064201810.1016/j.semcdb.2017.05.023ZouZChangHLiHWangSInduction of reactive oxygen species: An emerging approach for cancer therapyApoptosis2213211335201710.1007/s10495-017-1424-928936716RodicSVincentMDReactive oxygen species (ROS) are a key determinant of Cancer's metabolic phenotypeInt J Cancer142440448201810.1002/ijc.31069WangSLuoJZhangZDongDShenYFangYHuLLiuMDaiCPengSIron and magnetic: New research direction of the ferroptosis-based cancer therapyAm J Cancer Res8193319462018304168466220147SnezhkinaAVKudryavtsevaAVKardymonOLSavvateevaMVMelnikovaNVKrasnovGSDmitrievAAROS Generation and antioxidant defense systems in normal and malignant cellsOxid Med Cell Longev20196175804201910.1155/2019/6175804314676346701375HelfingerVSchröderKRedox control in cancer development and progressionMol Aspects Med638898201810.1016/j.mam.2018.02.00329501614Sánchez-SánchezAMMartínVGarcía-SantosGRodríguez-BlancoJCasado-ZapicoSSuarez-GarnachoSAntolínIRodriguezCIntracellular redox state as determinant for melatonin antiproliferative vs cytotoxic effects in cancer cellsFree Radic Res4513331341201110.3109/10715762.2011.62370021923620KlaunigJEOxidative stress and cancerCurr Pharm Des2447714778201810.2174/1381612825666190215121712XieQLanGZhouYHuangJLiangYZhengWFuXFanCChenTStrategy to enhance the anticancer efficacy of X-ray radiotherapy in melanoma cells by platinum complexes, the role of ROS-mediated signaling pathwaysCancer Lett3545867201410.1016/j.canlet.2014.07.04625135223GaleazCTotisCBisioARadiation resistance: A matter of transcription factorsFront Oncol11662840202110.3389/fonc.2021.662840341416168204019SonisSTSuperoxide dismutase as an intervention for radiation therapy-associated toxicities: Review and profile of avasopasem manganese as a treatment option for radiation-induced mucositisDrug Des Devel Ther1510211029202110.2147/DDDT.S267400337165007944116PerilloBDi DonatoMPezoneADi ZazzoEGiovannelliPGalassoGCastoriaGMigliaccioAROS in cancer therapy: The bright side of the moonExp Mol Med52192203202010.1038/s12276-020-0384-2320603547062874KimSJKimHSSeoYRUnderstanding of ROS-inducing strategy in anticancer therapyOxid Med Cell Longev20195381692201910.1155/2019/5381692HuJLiYLiHShiFXieLZhaoLTangMLuoXJiaWFanJTargeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapyTheranostics101192111937202010.7150/thno.46006332043207667690PopracPJomovaKSimunkovaMKollarVRhodesCJValkoMTargeting free radicals in oxidative stress-related human diseasesTrends Pharmacol Sci38592607201710.1016/j.tips.2017.04.00528551354JiangHWangHDe RidderMTargeting antioxidant enzymes as a radiosensitizing strategyCancer Lett438154164201810.1016/j.canlet.2018.09.00430223069JaganjacMMilkovicLSunjicSBZarkovicNThe NRF2, Thioredoxin, and Glutathione system in tumorigenesis and anticancer therapiesAntioxidants (Basel)9E1151202010.3390/antiox9111151ReczekCRChandelNSThe two faces of reactive oxygen species in cancerAnn Rev Cancer Biol17998201710.1146/annurev-cancerbio-041916-065808KoyamaHNojiriHKawakamiSSunagawaTShirasawaTShimizuTAntioxidants improve the phenotypes of dilated cardiomyopathy and muscle fatigue in mitochondrial superoxide dismutase-deficient miceMolecules1813831393201310.3390/molecules18021383233489926269947IghodaroOMAkinloyeOAFirst line defence antioxidantssuperoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence gridAlexandria J Med54287293201810.1016/j.ajme.2017.09.001HaddadMHervéVBen KhedherMRRabanelJMRamassamyCGlutathione: An old and small molecule with great functions and new applications in the brain and in Alzheimer's diseaseAntioxid Redox Signal35270292202110.1089/ars.2020.812933637005MarroccoIAltieriFPelusoIMeasurement and clinical significance of biomarkers of oxidative stress in humansOxid Med Cell Longev20176501046201710.1155/2017/6501046286987685494111ZhangMLWuHTChenWJXuYYeQQShenJXLiuJInvolvement of glutathione peroxidases in the occurrence and development of breast cancersJ Transl Med18247202010.1186/s12967-020-02420-x325713537309991LiuXZhangYZhuangLOlszewskiKGanBNADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulationGenes Dis8731745202110.1016/j.gendis.2020.11.010345227048427322LiuJXiaXHuangPxCT: A critical molecule that links cancer metabolism to redox signalingMol Ther2823582366202010.1016/j.ymthe.2020.08.021329317517647670LuJChewEHHolmgrenATargeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxideProc Natl Acad Sci USA1041228812293200710.1073/pnas.0701549104176409171940330RenXZouLZhangXBrancoVWangJCarvalhoCHolmgrenALuJRedox signaling mediated by thioredoxin and glutathione systems in the central nervous systemAntioxid Redox Signal279891010201710.1089/ars.2016.6925284436835649126LiuTILuTYYangYCChangSHChenHHLuILSabuAChiuHCNew combination treatment from ROS-Induced sensitized radiotherapy with nanophototherapeutics to fully eradicate orthotopic breast cancer and inhibit metastasisBiomaterials257120229202010.1016/j.biomaterials.2020.12022932738654ShevtsovMSatoHMulthoffGShibataANovel approaches to improve the efficacy of immuno-RadiotherapyFront Oncol9156201910.3389/fonc.2019.00156309413086433964RabusHNanodosimetry-on the 'tracks' of biological radiation effectivenessZ Med Phys309194202010.1016/j.zemedi.2020.01.00232029295WangHJiangHVan De GuchtMDe RidderMHypoxic radioresistance: Can ROS be the key to overcome it?Cancers (Basel)11112201910.3390/cancers11010112AlizadehEOrlandoTMSancheLBiomolecular damage induced by ionizing radiation: The direct and indirect effects of low-energy electrons on DNAAnnu Rev Phys Chem66379398201510.1146/annurev-physchem-040513-10360525580626BaskarRDaiJWenlongNYeoRYeohKWBiological response of cancer cells to radiation treatmentFront Mol Biosci124201410.3389/fmolb.2014.00024259881654429645Le CaërSWater Radiolysis: Influence of oxide surfaces on H2 production under ionizing radiationWater3235253201110.3390/w3010235BaldacchinoGBrunEDendenIBouhadounSRouxRKhodjaHSicard-RoselliCImportance of radiolytic reactions during high-LET irradiation modalities: LET effect, role of O2 and radiosensitization by nanoparticlesCancer Nanotechnol103201910.1186/s12645-019-0047-yGongLZhangYLiuCZhangMHanSApplication of radiosensitizers in cancer radiotherapyInt J Nanomedicine1610831102202110.2147/IJN.S290438336033707886779CollinFChemical basis of reactive oxygen species reactivity and involvement in neurodegenerative diseasesInt J Mol Sci202407201910.3390/ijms201024076566277DayalRSinghAPandeyAMishraKPReactive oxygen species as mediator of tumor radiosensitivityJ Cancer Res Ther10811818201410.4103/0973-1482.146073AzzamEIJay-GerinJPPainDIonizing radiation-induced metabolic oxidative stress and prolonged cell injuryCancer Lett3274860201210.1016/j.canlet.2011.12.012RobinettZNBathlaGWuAClarkJJSibenallerZAWilsonTKirbyPAllenBGHansenMRPersistent oxidative stress in vestibular schwannomas after stereotactic radiation therapyOtol Neurotol3911841190201810.1097/MAO.0000000000001935301068456131037BuonannoMde ToledoSMPainDAzzamEILong-Term consequences of radiation-induced bystander effects depend on radiation quality and dose and correlate with oxidative stressRadiat Res175405415201110.1667/RR2461.1213199863106980ZhangQYWangFXJiaKKKongLDNatural product interventions for chemotherapy and radiotherapy-induced side effectsFront Pharmacol91253201810.3389/fphar.2018.01253304596156232953MusaAEShabeebDAlhilfiHSQProtective effect of melatonin against radiotherapy-induced small intestinal oxidative stress: Biochemical evaluationMedicina (Kaunas)55308201910.3390/medicina55060308LeiGMaoCYanYZhuangLGanBFerroptosis, radiotherapy, and combination therapeutic strategiesProtein Cell12836857202110.1007/s13238-021-00841-y338913038563889LiuBBhattDOltvaiZNGreenbergerJSBaharISignificance of p53 dynamics in regulating apoptosis in response to ionizing radiation and polypharmacological strategiesSci Rep46245201410.1038/srep06245ZanellaFLinkWCarneroAUnderstanding FOXO, new views on old transcription factorsCurr Cancer Drug Targets10135146201010.2174/15680091079105415820088800Schmidt-UllrichRKContessaJNLammeringGAmorinoGLinPSERBB receptor tyrosine kinases and cellular radiation responsesOncogene2258555865200310.1038/sj.onc.120669812947392DixonSJLembergKMLamprechtMRSkoutaRZaitsevEMGleasonCEPatelDNBauerAJCantleyAMYangWSFerroptosis: An iron-dependent form of non-apoptotic cell deathCell14910601072201210.1016/j.cell.2012.03.042226329703367386ZhuJXiongYZhangYWenJCaiNChengKLiangHZhangWThe molecular mechanisms of regulating oxidative stress-induced ferroptosis and therapeutic strategy in tumorsOxid Med Cell Longev20208810785202010.1155/2020/8810785BarreraGOxidative stress and lipid peroxidation products in cancer progression and therapyISRN Oncol20121372892012231191853483701StockwellBRJiangXGuWEmerging mechanisms and disease relevance of ferroptosisTrends Cell Biol30478490202010.1016/j.tcb.2020.02.009324133177230071LangXGreenMDWangWYuJChoiJEJiangLLiaoPZhouJZhangQDowARadiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11Cancer Discov916731685201910.1158/2159-8290.CD-19-0338315546426891128LiXDuanLYuanSZhuangXQiaoTHeJFerroptosis inhibitor alleviates Radiation-induced lung fibrosis (RILF) via down-regulation of TGF-β1J Inflamm (Lond)1611201910.1186/s12950-019-0216-0LeiGZhangYKoppulaPLiuXZhangJLinSHAjaniJAXiaoQLiaoZWangHGanBThe role of ferroptosis in ionizing radiation-induced cell death and tumor suppressionCell Res30146162202010.1038/s41422-019-0263-3319492857015061LiJCaoFYinHLHuangZJLinZTMaoNSunBWangGFerroptosis: Past, present and futureCell Death Dis1188202010.1038/s41419-020-2298-2320153256997353JiangLKonNLiTWangSJSuTHibshooshHBaerRGuWFerroptosis as a p53-mediated activity during tumour suppressionNature5205762201510.1038/nature14344257999884455927DodsonMCastro-PortuguezRZhangDDNRF2 plays a critical role in mitigating lipid peroxidation and ferroptosisRedox Biol23101107201910.1016/j.redox.2019.101107306920386859567CameronBDSekharKROforiMFreemanMLThe role of Nrf2 in the response to normal tissue radiation injuryRadiat Res19099106201810.1667/RR15059.1297993196093213SekharKRFreemanMLNrf2 promotes survival following exposure to ionizing radiationFree Radic Biol Med88268274201510.1016/j.freeradbiomed.2015.04.035259759854628893FengLZhaoKSunLYinXZhangJLiuCLiBSLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosisJ Transl Med19367202110.1186/s12967-021-03042-7344460458393811LippmannJPetriKFuldaSLieseJRedox modulation and induction of ferroptosis as a new therapeutic strategy in hepatocellular carcinomaTransl Oncol13100785202010.1016/j.tranon.2020.100785324164407283515JakobsPSerbuleaVLeitingerNEckersAHaendelerJNuclear factor (Erythroid-Derived 2)-Like 2 and Thioredoxin-1 in atherosclerosis and ischemia/reperfusion injury in the heartAntioxid Redox Signal26630644201710.1089/ars.2016.67955397216BanningADeubelSKluthDZhouZBrigelius-FlohéRThe GI-GPx Gene Is a target for Nrf2Mol Cell Biol2549144923200510.1128/MCB.25.12.4914-4923.2005159236101140597KimYJAhnJYLiangPIpCZhangYParkYMHuman prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: Implication to tumor biologyCancer Res67546554200710.1158/0008-5472.CAN-06-240117234762FisherABPeroxiredoxin 6: A Bifunctional enzyme with glutathione peroxidase and phospholipase A2 activitiesAntioxid Redox Signal15831844201110.1089/ars.2010.34123125547YangHMagilnickNLeeCKalmazDOuXChanJYLuSCNrf1 and Nrf2 regulate rat glutamate-cysteine ligase catalytic subunit transcription indirectly via NF-kappaB and AP-1Mol Cell Biol2559335946200510.1128/MCB.25.14.5933-5946.2005159880091168815SinhaKDasJPalPBSilPCOxidative stress: The mitochondria-dependent and mitochondria-independent pathways of apoptosisArch Toxicol8711571180201310.1007/s00204-013-1034-423543009ChenKWDemarcoBHeiligRShkarinaKBoettcherAFaradyCJPelczarPBrozPExtrinsic and intrinsic apoptosis activate pannexin-1 to drive NLRP3 inflammasome assemblyEMBO J38e101638201910.15252/embj.2019101638309028486517827CaoXWenPFuYGaoYQiXChenBTaoYWuLXuALuHZhaoGRadiation induces apoptosis primarily through the intrinsic pathway in mammalian cellsCell Signal62109337201910.1016/j.cellsig.2019.06.00231173879LiuCMannDSinhaUKKokotNCThe molecular mechanisms of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): An extensive reviewJ Otolaryngol Head Neck Surg4759201810.1186/s40463-018-0302-y302415726150985MendesFSalesTDominguesCSchugkSAbrantesAMGonçalvesACTeixoRSilvaRCasalta-LopesJRochaCEffects of X-radiation on lung cancer cells: the interplay between oxidative stress and P53 levelsMed Oncol32266201510.1007/s12032-015-0712-x26582337MortezaeeKNajafiMFarhoodBAhmadiAPotesYShabeebDMusaAEModulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated reviewLife Sci228228241201910.1016/j.lfs.2019.05.00931077716QinCChenXBaiQDavisMRFangYFactors associated with radiosensitivity of cervical cancerAnticancer Res3446494656201425202040KimWLeeSSeoDKimDKimKKimEKangJSeongKMYounHYounBCellular stress responses in radiotherapyCells81105201910.3390/cells80911056769573ChangHWLeeMLeeYSKimSHLeeJCParkJJNamHYKimMRHanMWKimSWKimSYp53-dependent glutamine usage determines susceptibility to oxidative stress in radioresistant head and neck cancer cellsCell Signal77109820202110.1016/j.cellsig.2020.109820MayaRBalassMKimSTShkedyDLealJFShifmanOMoasMBuschmannTRonaiZShilohYATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damageGenes Dev1510671077200110.1101/gad.88690111331603312683KimEMJungCHKimJHwangSGParkJKUmHDThe p53/p21 complex regulates cancer cell invasion and apoptosis by targeting Bcl-2 family proteinsCancer Res7730923100201710.1158/0008-5472.CAN-16-209828377455BudanovAVThe role of tumor suppressor p53 in the antioxidant defense and metabolismSubcell Biochem85337358201410.1007/978-94-017-9211-0_18252012034206257RastogiSRizwaniWJoshiBKunigalSChellappanSPTNF-α response of vascular endothelial and vascular smooth muscle cells involve differential utilization of ASK1 kinase and p73Cell Death Differ19274283201210.1038/cdd.2011.93FelthamRJamalKTenevTLiccardiGJacoIDominguesCMMorrisOJohnSWAnnibaldiAWidyaMMind bomb regulates cell death during TNF signaling by suppressing RIPK1's cytotoxic potentialCell Rep23470484201810.1016/j.celrep.2018.03.054296420055912950KokolakisGSabatRKrüger-KrasagakisSEberleJAmbivalent effects of tumor necrosis factor alpha on apoptosis of malignant and normal human keratinocytesSkin Pharmacol Physiol3494102202110.1159/00051372533730739StoytchevaZRBerryMJTranscriptional regulation of mammalian selenoprotein expressionBiochim Biophys Acta179014291440200910.1016/j.bbagen.2009.05.012194650842764002RossMJMartinkaSD'AgatiVDBruggemanLANF-kappaB regulates Fas-mediated apoptosis in HIV-associated nephropathyJ Am Soc Nephrol1624032411200510.1681/ASN.2004121101159759992203217MorganMJLiuZCrosstalk of reactive oxygen species and NF-κB signalingCell Res21103115201110.1038/cr.2010.178LiQSunYLiuBLiJHaoXGeWZhangXBaoSGongJJiangZACT001 modulates the NF-κB/MnSOD/ROS axis by targeting IKKβ to inhibit glioblastoma cell growthJ Mol Med (Berl)98263277202010.1007/s00109-019-01839-0KumarSClairDSRadioresistance in prostate cancer: Focus on the interplay between NF-κB and SODAntioxidants (Basel)101925202110.3390/antiox10121925SohRHardyAZur NiedenNIThe FOXO signaling axis displays conjoined functions in redox homeostasis and stemnessFree Radic Biol Med169224237202110.1016/j.freeradbiomed.2021.04.02233878426PonugotiBDongGGravesDTRole of forkhead transcription factors in diabetes-induced oxidative stressExp Diabetes Res2012939751201210.1155/2012/939751224546323290826YangJYXiaWHuMCIonizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosisInt J Oncol296436482006168652802632978LimSWJinLLuoKJinJShinYJHongSYYangCWKlotho enhances FoxO3-mediated manganese superoxide dismutase expression by negatively regulating PI3K/AKT pathway during tacrolimus-induced oxidative stressCell Death Dis8e2972201710.1038/cddis.2017.365287712275596554TsengAHWuLHShiehSSWangDLSIRT3 interactions with FOXO3 acetylation, phosphorylation and ubiquitinylation mediate endothelial cell responses to hypoxiaBiochem J464157168201410.1042/BJ2014021325162939WangYChenSLiHHydrogen peroxide stress stimulates phosphorylation of FoxO1 in rat aortic endothelial cellsActa Pharmacol Sin31160164201010.1038/aps.2009.201201398984002846GuanLZhangLGongZHouXXuYFengXWangHYouHFoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signalingHepatology6319141927201610.1002/hep.2849626857210AraujoJBreuerPDieringerSKraussSDornSZimmermannKPfeiferAKlockgetherTWuellnerUEvertBOFOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3Hum Mol Genet2029282941201110.1093/hmg/ddr19721536589RachedMTKodeAXuLYoshikawaYPaikJHDePinhoRAKousteniSFoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblastsCell Metab11147160201010.1016/j.cmet.2010.01.001201421022820405YePMimuraJOkadaTSatoHLiuTMaruyamaAOhyamaCItohKNrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibitionMol Cell Biol3434213434201410.1128/MCB.00221-14250025274135628WangZErbB receptors and cancerMethods Mol Biol1652335201710.1007/978-1-4939-7219-7_128791631ValerieKYacoubAHaganMPCurielDTFisherPBGrantSDentPRadiation-induced cell signaling: Inside-out and outside-inMol Cancer Ther6789801200710.1158/1535-7163.MCT-06-059617363476Appert-CollinAHubertPCrémelGBennasrouneARole of ErbB receptors in cancer cell migration and invasionFront Pharmacol6283201510.3389/fphar.2015.00283266356124657385WeePWangZEpidermal growth factor receptor cell proliferation signaling pathwaysCancers (Basel)952201710.3390/cancers9050052RezatabarSKarimianARameshkniaVParsianHMajidiniaMKopiTABishayeeASadeghiniaAYousefiMMonirialamdariMYousefiBRAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progressionJ Cell PhysiolFeb272019Epub ahead of print10.1002/jcp.2833430811039KimMJChoiWGAhnKJChaeIGYuRBackSHReduced EGFR level in eIF2α PhosphorylationDeficient hepatocytes is responsible for susceptibility to oxidative stressMol Cells432642752020321507947103887ZhangWYangHZhuLLuoYNieLLiGRole of EGFR/ErbB2 and PI3K/AKT/e-NOS in Lycium barbarum polysaccharides ameliorating endothelial dysfunction induced by oxidative stressAm J Chin Med4715231539201910.1142/S0192415X19500782BoeckxCVan den BosscheJDe PauwIPeetersMLardonFBaayMWoutersAThe hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: Preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell linesBMC Res Notes8203201510.1186/s13104-015-1197-6260327264467624BierlCVoetschBJinRCHandyDELoscalzoJDeterminants of human plasma glutathione peroxidase (GPx-3) expressionJ Biol Chem2792683926845200410.1074/jbc.M40190720015096516TonelliCChioIICTuvesonDATranscriptional regulation by Nrf2Antioxid Redox Signal2917271745201810.1089/ars.2017.73426208165KangHJYiYWHongYBKimHJJangYJSeongYSBaeIHER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interactionSci Rep47201201410.1038/srep07201254671934252900SakuraiANishimotoMHimenoSImuraNTsujimotoMKunimotoMHaraSTranscriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: Role of NF-E2-related factor-2J Cell Physiol203529537200510.1002/jcp.20246GordonLIBurkeMASinghATPrachandSLiebermanEDSunLNaikTJPrasadSVArdehaliHBlockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathwaysJ Biol Chem28420802087200910.1074/jbc.M8045702002629107AllegraAGManninoFInnaoVMusolinoCAllegraARadioprotective agents and enhancers factors Preventive and therapeutic strategies for oxidative induced radiotherapy damages in hematological malignanciesAntioxidants (Basel)91116202010.3390/antiox9111116Jasek-GajdaEJurkowskaHJasińskaMLisGJTargeting the MAPK/ERK and PI3K/AKT signaling pathways affects NRF2, Trx and GSH antioxidant systems in leukemia cellsAntioxidants (Basel)9633202010.3390/antiox9070633ChenQMMaltagliatiAJNrf2 at the heart of oxidative stress and cardiac protectionPhysiol Genomics507797201810.1152/physiolgenomics.00041.20175867612QinSHeXLinHSchulteBAZhaoMTewKDWangGYNrf2 inhibition sensitizes breast cancer stem cells to ionizing radiation via suppressing DNA repairFree Radic Biol Med169238247202110.1016/j.freeradbiomed.2021.04.006338921138138866SunXWangQWangYDuLXuCLiuQBrusatol enhances the radiosensitivity of A549 cells by promoting ROS production and enhancing DNA damageInt J Mol Sci17E997201610.3390/ijms17070997273479304964373LeeSLimMJKimMHYuCHYunYSAhnJSongJYAn effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responsesFree Radic Biol Med53807816201210.1016/j.freeradbiomed.2012.05.03822684019TsuchidaKTsujitaTHayashiMOjimaAKeleku-LukweteNKatsuokaFOtsukiAKikuchiHOshimaYSuzukiMYamamotoMHalofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulationFree Radic Biol Med103236247201710.1016/j.freeradbiomed.2016.12.04128039084ParkMKwonJShinHJMoonSMKimSBShinUSHanYHKimYButyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patient-derived organoidsInt J Oncol5713071318202010.3892/ijo.2020.5132331739757646587LiuZLiYSheGZhengXShaoLWangPPangMXieSSunYResveratrol induces cervical cancer HeLa cell apoptosis through the activation and nuclear translocation promotion of FOXO3aPharmazie75250254202032539920WangHBouzakouraSde MeySJiangHLawKDufaitICorbetCVerovskiVGevaertTFeronOAuranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen speciesOncotarget83572835742201710.18632/oncotarget.16113284157235482612XieQZhouYLanGYangLZhengWLiangYChenTSensitization of cancer cells to radiation by selenadiazole derivatives by regulation of ROS-mediated DNA damage and ERK and AKT pathwaysBiochem Biophys Res Commun4498893201410.1016/j.bbrc.2014.04.15124813998LiangYWZhengJLiXZhengWChenTSelenadiazole derivatives as potent thioredoxin reductase inhibitors that enhance the radiosensitivity of cancer cellsEur J Med Chem84335342201410.1016/j.ejmech.2014.07.03225036792JiaJJGengWSWangZQChenLZengXSThe role of thioredoxin system in cancer: Strategy for cancer therapyCancer Chemother Pharmacol84453470201910.1007/s00280-019-03869-431079220KimpleRJVasevaAVCoxADBaermanKMCalvoBFTepperJEShieldsJMSartorCIRadiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational statusClin Cancer Res16912923201010.1158/1078-0432.CCR-09-1324201036652818631ZhangSFuYWangDWangJIcotinib enhances lung cancer cell radiosensitivity in vitro and in vivo by inhibiting MAPK/ERK and AKT activationClin Exp Pharmacol PhysiolMay162018Epub ahead of print10.1111/1440-1681.12966YiHYanXLuoQYuanLLiBPanWZhangLChenHWangJZhangYA novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinomaJ Exp Clin Cancer Res3797201810.1186/s13046-018-0765-8297166225930807WangJWangHQianHBiological effects of radiation on cancer cellsMil Med Res5202018299585456026344DesoukyODingNZhouGTargeted and non-targeted effects of ionizing radiationJ Radiation Res App Sci82472542015De RuysscherDNiedermannGBurnetNGSivaSLeeAWMHegi-JohnsonFRadiotherapy toxicityNat Rev Dis Primers513201910.1038/s41572-019-0064-530792503MukherjeeDCoatesPJLorimoreSAWrightEGResponses to ionizing radiation mediated by inflammatory mechanismsJ Pathol232289299201410.1002/path.4299LeBaronTWKuraBKalocayovaBTribulovaNSlezakJA new approach for the prevention and treatment of cardiovascular disorders. Molecular Hydrogen Significantly Reduces the Effects of Oxidative StressMolecules242076201910.3390/molecules241120766600250EbrahimiSSoltaniAHashemySIOxidative stress in cervical cancer pathogenesis and resistance to therapyJ Cell BiochemNov132018Epub ahead of print30426530GudkovAVKomarovaEAThe role of p53 in determining sensitivity to radiotherapyNat Rev Cancer3117129200310.1038/nrc99212563311LiPZhaoQLWuLHJawaidPJiaoYFKadowakiMKondoTIsofraxidin, a potent reactive oxygen species (ROS) scavenger, protects human leukemia cells from radiation-induced apoptosis via ROS/mitochondria pathway in p53-independent mannerApoptosis1910431053201410.1007/s10495-014-0984-124692054QinHZhangHZhangXZhangSZhuSWangHResveratrol attenuates radiation enteritis through the SIRT1/FOXO3a and PI3K/AKT signaling pathwaysBiochem Biophys Res Commun554199205202110.1016/j.bbrc.2021.03.12233812084NuszkiewiczJWoźniakASzewczyk-GolecKIonizing radiation as a source of oxidative stress-the protective role of melatonin and vitamin DInt J Mol Sci215804202010.3390/ijms21165804FarhoodBGoradelNHMortezaeeKKhanlarkhaniNSalehiENashtaeiMSMirtavoos-MahyariHMotevaseliEShabeebDMusaAENajafiMMelatonin as an adjuvant in radiotherapy for radioprotection and radiosensitizationClin Transl Oncol21268279201910.1007/s12094-018-1934-0Batinic-HaberleITovmasyanASpasojevicIMn Porphyrin-based redox-active drugs: Differential effects as cancer therapeutics and protectors of normal tissue against oxidative injuryAntioxid Redox Signal2916911724201810.1089/ars.2017.7453299267556207162Batinic-HaberleITovmasyanAHuangZDuanWDuLSiamakpour-ReihaniSCaoZShengHSpasojevicIAlvarez SecordAH2O2-Driven Anticancer Activity of Mn Porphyrins and the underlying molecular pathwaysOxid Med Cell Longev20216653790202110.1155/2021/6653790
KEGG pathway enrichment analysis of oxidative stress-related genes. The rich factor resembles the ratio of the number of target genes annotated in this pathway. KEGG, Kyoto Encyclopedia of Genes and Genomes.
Antioxidant system response to radiotherapy. H2O2 is generated through water radiolysis, which may be transformed into the highly reactive OH through the Fenton reaction. SOD is an important metalloenzyme that catalyzes O2− to molecular oxygen O2 and H2O2. H2O2 may be transformed to H2O by the enzymes CAT, GPX or TrxR. CAT is a common antioxidant enzyme from the family of oxyreductases. GSH and Trx are two thiol-dependent redox systems acting in concert, which have been identified as powerful antioxidant mechanisms. These enzymes may effectively scavenge H2O2. The yellow color corresponds to the four main antioxidant enzyme systems. Oxidized and reduced states are indicated by red or blue color, respectively. H2O2, hydrogen peroxide;·OH, hydroxyl radical; SOD, superoxide dismutase; CAT, catalase; GPX, glutathione peroxidase; Trx, thioredoxin; TrxR, Trx reductase; GSH, glutathione; O2, molecular oxygen; O −2, superoxide anion; GCL, glutamate-cysteine ligase; GSS, GSH synthetase; GR, GSH reductase; Prx, peroxiredoxin; IR, ionizing radiation; SLC3A2, solute carrier family 3 member 2; e−aq, hydrated electrons.
Activation of oxidative stress-related pathways by radiotherapy. In response to IR, activated ErbB1 and ErbB2 (via interaction with one of the ligand-bound partners) induce the subsequent activation of downstream signaling pathways that include MAPK, PI3K/AKT and FoxO. The activation of the MAPK and PI3K/AKT signaling pathways increases the expression levels of Nrf2, thereby activating several antioxidant systems in response to oxidative stress. The FoxO-target genes include various genes encoding antioxidant proteins, which have a complex role in the induction of oxidative stress. It may not only activate the antioxidant system to promote tumor cell survival, but also promote apoptosis. NF-κB is another key pathway regulating the fine balance of the cellular redox status. The binding of the NF-κB proteins to DNA regulates the transcription of various potential antioxidant targets. In addition, IR activates the SLC7A11/GPX4 axis, which is considered to be one of the most important means of regulating oxidative stress via the ferroptotic pathway. IR, ionizing radiation; ErbB, Erb-b receptor tyrosine kinase; FoxO, forkhead box protein O; SLC7A11, solute carrier family 7 member 11; GPX4, glutathione reductase 4; SOD, superoxide dismutase; CAT, catalase; Trx, thioredoxin; Nrf2, nuclear factor-erythroid factor 2-related factor 2.
Regulation of radiotherapy by targeting antioxidant enzyme systems.